Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

i>In controlled Crohn's clinical trials, the most common adverse events that occurred in greater than or equal to 5% of certolizumab Pegol patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% certolizumab pegol, 13% placebo), urinary tract infection (7% certolizumab pegol, 6% placebo), and arthralgia (6% certolizumab pegol, 4% placebo).  The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for certolizumab pegol and 7% for placebo.

In controlled RA clinical trials, the most common adverse events that occurred in greater than or equal to 3% of patients taking certolizumab pegol 200 mg every other week with concomitant methotrexate (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% certolizumab pegol, 2% placebo), headache (5% certolizumab pegol, 4% placebo), hypertension (5% certolizumab pegol, 2% placebo), nasopharyngitis (5% certolizumab pegol, 1% placebo), back pain (4% certolizumab pegol, 1% placebo), pyrexia (3% certolizumab pegol, 2% placebo), pharyngitis (3% certolizumab pegol, 1% placebo), rash (3% certolizumab pegol, 1% placebo), acute bronchitis (3% certolizumab pegol,1% placebo), fatigue (3% certolizumab pegol, 1% placebo).  Hypertensive adverse reactions were observed more frequently in patients receiving certolizumab pegol than in controls.  These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and nonsteroidal anti-inflammatory drugs.  Patients receiving certolizumab pegol 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving certolizumab pegol 200mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. Marken Rapidly Responds to Global Supply Chain Security Measures
10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Simplified Genetics ... for improved fitness, health and safety in the U.S., announced ... the personal roadmap to improved overall health found within specific ... of your cheek. The tests include ... is a full sequence genetic analysis that maps four key ...
(Date:9/2/2015)... Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... President and Chief Executive Officer, will present a ... Investment Conference, sponsored by H.C. Wainwright ... 8-10, 2015 at the St. Regis Hotel in ...
(Date:9/2/2015)... Sept. 2, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... call to discuss its financial results for the third ... call will be at 4:30 p.m. ET on Thursday, ... for the third quarter of fiscal 2015 after the ... Participants can dial (877) 317-6789 or (412) 317-6789 ...
Breaking Medicine Technology:Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2
... MOUNTAIN VIEW, Calif., Sept. 8, 2011 Concentric Medical, Inc., ... completion of enrollment of the TREVO Study.  The TREVO Study ... of large V essel O ... of Stentriever™ technology in a European, multicenter, prospective clinical trial. ...
... Sept. 8, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced additional three year recurrence data from ... Evaluation of Success Study (CORDLESS) for XIAFLEX ® ... adult Dupuytren,s contracture patients with a palpable cord. ...
Cached Medicine Technology:Concentric Medical Completes Enrollment in Prospective Multi Center Stentriever™ Trial for Mechanical Thrombectomy in Stroke 2Concentric Medical Completes Enrollment in Prospective Multi Center Stentriever™ Trial for Mechanical Thrombectomy in Stroke 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 2Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 4Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 5Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 6Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 7Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 8Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 9
(Date:9/2/2015)... ... , ... Every year at this time, students prepare to go back to ... face the academic workload confronting them. They just don’t have the skills needed to ... teach students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces Hand Free Pocket Cop, a safety invention that protects people from crime ... worth $31 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:9/2/2015)... ... , ... Ovarian cancer continues to be the deadliest of all gynecologic cancers. ... her lifetime is approximately 1 in 75. This year it is estimated that approximately ... , There is no test to detect ovarian cancer. A Pap test does ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... the pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream ... cream combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense ...
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a North Carolina ... Inc. 5000 List, an independent ranking of the fastest- growing private companies ... this achievement puts Canopy in rarefied company. Over the years, this elite group ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2
... groups were thought to be rare, but recent studies ... the thin beauty ideal. As a result, experts expect ... ethnic groups. It is also suspected that eating disorders ... boys. Although research has shown that eating disorders ...
... of the Charmin Restrooms to ... Times Square This Holiday Season, NEW YORK, Nov. ... free, fully-staffed public restrooms,in New York City as the Charmin(R) Restrooms ... Shannon will inaugurate the stalls,with the ceremonial "first flush" and ribbon ...
... Family Caregiver,s Month; Announces Availability ... More than 34 Million Caregivers, PALO ALTO, Calif., Nov. ... proud to support the more than 34 million,Americans caring for ... availability of its website. Designed to give caregivers the ...
... Flow Cytometry Portfolio Targeted at Fast Growing ... ... Nov. 19, Beckman Coulter, Inc. (NYSE: BEC ), a leading,developer ... A/S, a world leader in cancer diagnostics,announced today that Beckman Coulter ...
... REDWOOD CITY, Calif., Nov. 19 People grow ... is no different. SleepQuest, the leader in,at-home diagnostic ... growing pains which accompany rapid growth by moving ... INC. Magazine,s 5000 Fastest Growing Private,Companies in America, ...
... GNC is joining St. Jude Children,s,Research Hospital as ... is the fourth year for the national campaign and ... in the effort. Thanks and Giving was created ... Thomas and her siblings, Terre and Tony,Thomas, the children ...
Cached Medicine News:Health News:Eating disorders in adolescents 2Health News:Eating disorders in adolescents 3Health News:Video: Charmin's Gift That Keeps on Giving! 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 3Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 2Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 3Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 3
Stryker Endoscopy offers a superior selection of probes and tips that interface with our suction and irrigation system....
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease....
... revolutionary flexibility to floor-mounted X-ray systems. ... move the C-arm around the exam ... optimal angle for cardiac and general ... cardiac flat panel detector that delivers ...
... pH.p Capsule passes through the GI tract, it ... frequencies to the SmartPill Data Receiver, a small, ... the patient (supported by either a belt or ... and pH measurement data, and elapsed and real ...
Medicine Products: